AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34029129 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 1
Study 34069117 — intervention group
Group type: EXPERIMENTAL
Intervention: HC diet with 1% sodium butyrate (HCSB)
Number of subjects: 80
Study 34069117 — intervention group
Group type: EXPERIMENTAL
Intervention: HC diet with 1% sodium β‐hydroxybutyrate (HCHB)
Number of subjects: 80
Study 34069117 — intervention group
Group type: COMPARATOR
Intervention: HC diet
Number of subjects: 80
Study 34069117 — intervention group
Group type: COMPARATOR
Intervention: Low-concentrate (LC) diet
Number of subjects: 80
Study 32173886 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial photobiomodulation (tPBM) with 1,064-nm laser
Number of subjects: 20
Study 32173886 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study 34339697 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal glyphosate exposure
Number of subjects: 163
Study 34339697 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal AMPA exposure
Number of subjects: 163
Study 34339697 — intervention group
Group type: EXPERIMENTAL
Intervention: Binary analysis of glyphosate and AMPA
Number of subjects: 163
Study 33159620 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration at 18 Hz
Number of subjects: 0
Study 33159620 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration at 6 Hz
Number of subjects: 0
Study 33159620 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration at 12 Hz
Number of subjects: 0
Study 33159620 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 33227833 — intervention group
Group type: EXPERIMENTAL
Intervention: FM‐UD+HBO2
Number of subjects: 20
Study 33227833 — intervention group
Group type: COMPARATOR
Intervention: FM‐UD
Number of subjects: 20
Study 35832019 — intervention group
Group type: EXPERIMENTAL
Intervention: Villages et Écoles Assainis (VEA) programme
Number of subjects: 332
Study 35832019 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 332
Study 34899124 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural therapy (biofeedback training)
Number of subjects: 50
Study 34899124 — intervention group
Group type: COMPARATOR
Intervention: Interferential current training
Number of subjects: 50
Study 35589610 — intervention group
Group type: EXPERIMENTAL
Intervention: Ladarixin (LDX) 400 mg twice-daily for three cycles of 14 days on/14 days off
Number of subjects: 76
Study 35589610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 35589610 — intervention group
Group type: EXPERIMENTAL
Intervention: Ladarixin (LDX)
Number of subjects: 76
Study 33130034 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Circuit Training (HICT)
Number of subjects: 33
Study 33130034 — intervention group
Group type: COMPARATOR
Intervention: Control (HICT performed twice at baseline and end)
Number of subjects: 33
Study 35725754 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model based on peritumoral radiomics features
Number of subjects: 339
Study 35725754 — intervention group
Group type: COMPARATOR
Intervention: Conventional model based on tumor consolidation/tumor (C/T) ratio
Number of subjects: 339
Study 35725754 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics model for STAS prediction
Number of subjects: 339
Study 35725754 — intervention group
Group type: COMPARATOR
Intervention: Lobectomy patients
Number of subjects: 339
Study 34378672 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (painful TMJ clicking)
Number of subjects: 90
Study 34378672 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (painless TMJ clicking)
Number of subjects: 90
Study 34378672 — intervention group
Group type: COMPARATOR
Intervention: Group 3 (control group)
Number of subjects: 90
Study 35372636 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 180
Study 35372636 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorial saturation
Number of subjects: 180
Study 35372636 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 180
Study 32065861 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquablation therapy
Number of subjects: 181
Study 32065861 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 181
Study 35575732 — intervention group
Group type: EXPERIMENTAL
Intervention: It Gets Better project (IGBP) videos (n=242)
Number of subjects: 483
Study 35575732 — intervention group
Group type: COMPARATOR
Intervention: Control video (n=241)
Number of subjects: 483
Study 32200225 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment targeting reductions in negative affect or increases in positive affect (15 sessions)
Number of subjects: 35
Study 32200225 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol reactivity (measured as peak during stress task minus basal level)
Number of subjects: 35
Study 32200225 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol reactivity
Number of subjects: 35
Study 33942327 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma therapy (CPT), median volume of 828 ml (range: 817–960), administered 14 days after ICU admission.
Number of subjects: 14
Study 33942327 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma therapy (CPT)
Number of subjects: 14
Study 34930267 — intervention group
Group type: EXPERIMENTAL
Intervention: Cipargamin (10 to 150 mg single doses and 10 to 50 mg once daily for 3 days)
Number of subjects: 186
Study 34930267 — intervention group
Group type: COMPARATOR
Intervention: Artemether–lumefantrine (control)
Number of subjects: 186
Study 32527382 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care treatment
Number of subjects: 288
Study 32527382 — intervention group
Group type: COMPARATOR
Intervention: Specialist outpatient care
Number of subjects: 288
Study 34358491 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body hypothermia (33·5°C) for 72 h
Number of subjects: 408
Study 34358491 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 408
Study 33250082 — intervention group
Group type: EXPERIMENTAL
Intervention: Netarsudil 0.02% QD
Number of subjects: 386
Study 33250082 — intervention group
Group type: EXPERIMENTAL
Intervention: Netarsudil 0.02% BID
Number of subjects: 386
Study 33250082 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% BID
Number of subjects: 386
Study 36394727 — intervention group
Group type: EXPERIMENTAL
Intervention: MIRE exposure and Tai Chi exercise (30 min MIRE + 40-45 min Tai Chi, 3 sessions/week)
Number of subjects: 49
Study 36394727 — intervention group
Group type: COMPARATOR
Intervention: Sham group (Tai Chi exercise only)
Number of subjects: 49
Study 34859493 — intervention group
Group type: EXPERIMENTAL
Intervention: Mevidalen 10 mg
Number of subjects: 344
Study 34859493 — intervention group
Group type: EXPERIMENTAL
Intervention: Mevidalen 30 mg
Number of subjects: 344
Study 34859493 — intervention group
Group type: EXPERIMENTAL
Intervention: Mevidalen 75 mg
Number of subjects: 344
Study 34859493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 344
Study 32662327 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-stand workstations (Group 1: 40:20, n=8; Group 2: 30:30, n=6; Group 3: 20:40, n=7)
Number of subjects: 32
Study 32662327 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual sitting, n=11)
Number of subjects: 32
Study 33523774 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide intranasal formulation with charcoal block
Number of subjects: 0
Study 33523774 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide intranasal formulation without charcoal block
Number of subjects: 0
Study 32073622 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual pill counting using a plastic dish and spatula
Number of subjects: 44
Study 32073622 — intervention group
Group type: EXPERIMENTAL
Intervention: Efforts put into pill counting
Number of subjects: 44
Study 32073622 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions alleviating the burden of pill counting
Number of subjects: 44
Study 33673587 — intervention group
Group type: EXPERIMENTAL
Intervention: Almonds (20% of daily energy consumption)
Number of subjects: 100
Study 33673587 — intervention group
Group type: COMPARATOR
Intervention: Calorie-matched snack (control)
Number of subjects: 100
Study 32391667 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 400 mg per day for 5 days plus conventional treatments
Number of subjects: 30
Study 32391667 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment only
Number of subjects: 30
Study 32391667 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 30
Study 35579297 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline infusion at a rate of 125 mL/h
Number of subjects: 450
Study 35579297 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/3-2/3 infusion at a rate of 125 mL/h
Number of subjects: 450
Study 35579297 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's lactate infusion at a rate of 125 mL/h
Number of subjects: 450
Study 35579297 — intervention group
Group type: COMPARATOR
Intervention: All groups (Normal saline, 1/3-2/3, Ringer's lactate)
Number of subjects: 450
Study 34869172 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-media training on HIV-related stigma
Number of subjects: 330
Study 34869172 — intervention group
Group type: COMPARATOR
Intervention: Control group (teachers without training)
Number of subjects: 330
Study 34869172 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents living with HIV
Number of subjects: 330
Study 36096824 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium citrate (350 mg elemental magnesium/day)
Number of subjects: 180
Study 36096824 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate binder sucroferric oxyhydroxide (1000 mg/day)
Number of subjects: 180
Study 36096824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 36096824 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium citrate + Phosphate binder
Number of subjects: 180
Study 33979464 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiyanping injection in combination with standard therapy
Number of subjects: 130
Study 33979464 — intervention group
Group type: COMPARATOR
Intervention: Standard supportive therapy alone
Number of subjects: 130
Study 34288256 — intervention group
Group type: EXPERIMENTAL
Intervention: OneCurve only
Number of subjects: 60
Study 34288256 — intervention group
Group type: EXPERIMENTAL
Intervention: OneG and OneCurve
Number of subjects: 60
Study 34288256 — intervention group
Group type: EXPERIMENTAL
Intervention: OneFlare and OneCurve
Number of subjects: 60
Study 34288256 — intervention group
Group type: EXPERIMENTAL
Intervention: OneFlare, OneG, and OneCurve
Number of subjects: 60
Study 34288256 — intervention group
Group type: COMPARATOR
Intervention: Glide-path preparation
Number of subjects: 60
Study 34485157 — intervention group
Group type: EXPERIMENTAL
Intervention: Endostar continuous intravenous infusion of anti‐angiogenic therapy plus CCRT
Number of subjects: 91
Study 34485157 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy for cervical cancer and paclitaxel combined with platinum chemotherapy (CCRT)
Number of subjects: 91
Study 32600386 — intervention group
Group type: EXPERIMENTAL
Intervention: radial extracorporeal shock wave therapy (rESWT)
Number of subjects: 200
Study 32600386 — intervention group
Group type: COMPARATOR
Intervention: sham-rESWT
Number of subjects: 200
Study 32600386 — intervention group
Group type: EXPERIMENTAL
Intervention: standardised exercise programme
Number of subjects: 200
Study 32600386 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 200
Study 32600386 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including rESWT, sham-rESWT, standardised exercise, and usual care)
Number of subjects: 200
Study 37450334 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette pack inserts with two response-efficacy messages and two self-efficacy messages
Number of subjects: 359
Study 37450334 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette pack inserts with self-efficacy messages
Number of subjects: 359
Study 37450334 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette pack inserts
Number of subjects: 359
Study 34080077 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral danirixin 75 mg twice daily
Number of subjects: 93
Study 34080077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 32473084 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical active lotion (Redensyl and Sepicontrol A5), applied twice daily for 24 weeks
Number of subjects: 44
Study 32473084 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control, applied twice daily for 24 weeks
Number of subjects: 44
Study 35662238 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse-fracture-prosthesis (RFP)
Number of subjects: 44
Study 35662238 — intervention group
Group type: COMPARATOR
Intervention: Common reverse-prosthesis (RP)
Number of subjects: 44
Study 32915514 — intervention group
Group type: EXPERIMENTAL
Intervention: Napping ≥5x/day at 1-month
Number of subjects: 126
Study 32915514 — intervention group
Group type: EXPERIMENTAL
Intervention: Each 1-hour increase in nocturnal sleep vs diurnal sleep
Number of subjects: 126
Study 32415211 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids and pregabalin
Number of subjects: 39
Study 32415211 — intervention group
Group type: COMPARATOR
Intervention: Opioids only
Number of subjects: 39
Study 35750501 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic ultrathin occlusal veneers (e.max CAD)
Number of subjects: 11
Study 35750501 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin ultrathin occlusal veneers (Lava Ultimate)
Number of subjects: 11
Study 36269028 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine + 0.5 mg/ml 0.02% oestradiol compound cream + oral placebo pill
Number of subjects: 100
Study 36269028 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressant nortriptyline + placebo cream
Number of subjects: 100
Study 36269028 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined peripheral cream and central pill treatments
Number of subjects: 100
Study 36269028 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream and placebo pill
Number of subjects: 100
Study 36269028 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 100
Study 34915854 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 71
Study 34915854 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 71
Study 33719918 — intervention group
Group type: EXPERIMENTAL
Intervention: High quality protein (30g/meal primarily from dairy) with caloric restriction (−500kcal/d) and low-intensity resistance exercise (30 min/3 times per week)
Number of subjects: 0
Study 33719918 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32920571 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 49
Study 32920571 — intervention group
Group type: COMPARATOR
Intervention: Control (no convalescent plasma)
Number of subjects: 49
Study 32920571 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma from donors with high levels of SARS-CoV-2 IgG and positive SARS-CoV-2 IgM
Number of subjects: 49
Study 35790976 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA
Number of subjects: 60
Study 35790976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 33622030 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio Visual Distraction (AVD)
Number of subjects: 100
Study 33622030 — intervention group
Group type: COMPARATOR
Intervention: Control (CTR)
Number of subjects: 100
Study 32819413 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 63
Study 32819413 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (SD)
Number of subjects: 63
Study 33150360 — intervention group
Group type: EXPERIMENTAL
Intervention: Truncated asparaginase treatment due to clinical toxicity (n = 358)
Number of subjects: 1401
Study 33150360 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without truncation (n = 1043)
Number of subjects: 1401
Study 33150360 — intervention group
Group type: EXPERIMENTAL
Intervention: Truncated asparaginase treatment or silent inactivation (n = 301)
Number of subjects: 1401
Study 33150360 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow relapse
Number of subjects: 1401
Study 33150360 — intervention group
Group type: EXPERIMENTAL
Intervention: Central nervous system relapse
Number of subjects: 1401
Study 35614156 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan ointment
Number of subjects: 24
Study 35614156 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 24
Study 33651470 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-soluble herbal acne patch (WHAP)
Number of subjects: 49
Study 33651470 — intervention group
Group type: COMPARATOR
Intervention: Hydrocolloid acne patch (HAP)
Number of subjects: 49
Study 33182295 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-workout supplement
Number of subjects: 23
Study 35864751 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Intervention (CI) - multifactorial training, 30 sessions
Number of subjects: 162
Study 35864751 — intervention group
Group type: COMPARATOR
Intervention: Control group - standard activities
Number of subjects: 162
Study 34288013 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-STELLA intervention (8-week videoconferencing components)
Number of subjects: 124
Study 33725178 — intervention group
Group type: EXPERIMENTAL
Intervention: VC+ group (500 mg/day PO for 45 days postoperatively)
Number of subjects: 98
Study 33725178 — intervention group
Group type: COMPARATOR
Intervention: VC- group (no supplementation)
Number of subjects: 98
Study 33478521 — intervention group
Group type: EXPERIMENTAL
Intervention: pegvorhyaluronidase alfa plus nab-paclitaxel/gemcitabine (PAG)
Number of subjects: 189
Study 32299454 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined extracorporeal shock wave lithotripsy (ESWL) and endoscopic treatment
Number of subjects: 106
Study 32299454 — intervention group
Group type: COMPARATOR
Intervention: Sham procedures
Number of subjects: 106
Study 32299454 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ESWL and endoscopic treatment
Number of subjects: 106
Study 36027559 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg once daily)
Number of subjects: 519
Study 36027559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 519
Study 33124886 — intervention group
Group type: EXPERIMENTAL
Intervention: iNOS inhibition (0.1 mM 1400W)
Number of subjects: 40
Study 33124886 — intervention group
Group type: COMPARATOR
Intervention: Control (lactated Ringer)
Number of subjects: 40
Study 33124886 — intervention group
Group type: EXPERIMENTAL
Intervention: iNOS inhibition
Number of subjects: 40
Study 32443298 — intervention group
Group type: EXPERIMENTAL
Intervention: low-dose recombinant tissue plasminogen activator (rt-PA)
Number of subjects: 88
Study 32443298 — intervention group
Group type: COMPARATOR
Intervention: non-rt-PA (saline)
Number of subjects: 88
Study 35232229 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 65
Study 35232229 — intervention group
Group type: COMPARATOR
Intervention: Sham EA
Number of subjects: 65
Study 33338496 — intervention group
Group type: EXPERIMENTAL
Intervention: ezParent (digital delivery of the Chicago Parent Program)
Number of subjects: 287
Study 33338496 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual-care control
Number of subjects: 287
Study 35818972 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient-based recommendations
Number of subjects: 240
Study 35818972 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient- and food-based recommendations
Number of subjects: 240
Study 35818972 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient-, food- and food-substitution-based recommendations
Number of subjects: 240
Study 35818972 — intervention group
Group type: COMPARATOR
Intervention: No recommendations (Control)
Number of subjects: 240
Study 35818972 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient-based, nutrient- and food-based, nutrient-, food- and food-substitution-based recommendations
Number of subjects: 240
Study 34411158 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150mg
Number of subjects: 18040
Study 34411158 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18040
Study 34411158 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110mg
Number of subjects: 18040
Study 33919800 — intervention group
Group type: EXPERIMENTAL
Intervention: Single LIST (1st LIST)
Number of subjects: 12
Study 33919800 — intervention group
Group type: EXPERIMENTAL
Intervention: Three consecutive LISTs
Number of subjects: 12
Study 33919800 — intervention group
Group type: EXPERIMENTAL
Intervention: Six consecutive LISTs
Number of subjects: 12
Study 32174447 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive comment intervention
Number of subjects: 0
Study 32174447 — intervention group
Group type: COMPARATOR
Intervention: Negative comment intervention
Number of subjects: 0
Study 36277984 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib plus docetaxel
Number of subjects: 84
Study 36277984 — intervention group
Group type: COMPARATOR
Intervention: Anlotinib
Number of subjects: 84
Study 34628881 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Ventilation (PCV)
Number of subjects: 48
Study 34628881 — intervention group
Group type: COMPARATOR
Intervention: Volume-Controlled Ventilation (VCV)
Number of subjects: 48
Study 35079761 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum CCFM16 for 28 days
Number of subjects: 103
Study 35079761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 35079761 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum CCFM16
Number of subjects: 103
Study 34447866 — intervention group
Group type: EXPERIMENTAL
Intervention: Scissor knife
Number of subjects: 10
Study 35490744 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenabasum (20 mg daily for 28 days, then 20 mg twice per day for 56 days)
Number of subjects: 22